Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: Tillomed Laboratories Ltd, 220 Butterfield, Great Marlings, Luton, LU2 8DL, United Kingdom
Norimode 2mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White, round, biconvex tablet of diameter 6.35mm, marked “T3” on one side, scored on reverse. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. |
Each tablet contains 2mg of Loperamide hydrochloride.
Excipients with known effect: Each Norimode 2mg tablet contains 110.356 mg lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Loperamide |
By binding to opiate receptors in the gut wall, loperamide hydrochloride reduces propulsive peristalsis, increases intestinal transit time and enhances resorption of water and electrolytes. Loperamide increases the tone of the anal sphincter, which helps reduce faecal incontinence and urgency. |
| List of Excipients |
|---|
|
Lactose monohydrate |
Blister Strip.
PVC: 250 micron, colourless.
Aluminium Foil: 20 micron.
3 such blister strips containing 10 tablets in an outer cardboard carton which also contains a Patient Information Leaflet.
Tillomed Laboratories Ltd, 220 Butterfield, Great Marlings, Luton, LU2 8DL, United Kingdom
PL 11311/0016
11/03/2009
| Drug | Countries | |
|---|---|---|
| NORIMODE | United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
